This is a $2,275,305.00 definitive cost-no-fee contract awarded by the U.S. Food and Drug Administration (FDA) to Children's Hospital Los Angeles (CHLA) with a performance period through June 16, 2024. The contract is for the development of a model that integrates inflammation and tissue injury to predict and mitigate the post-acute sequelae of COVID-19. As prime contractor, CHLA has subcontracted portions of the work to the University of Southern California and the University of California, Los Angeles. CHLA is an experienced federal contractor, having received numerous prior awards from agencies like the National Institutes of Health, Department of Health and Human Services, and Department of Defense to conduct research and provide clinical services. This specific contract did not use a set-aside designation.
Generated 6/13/24, 9:52 AM